2-(3-(5-((4-甲氧基苄基)氧基)吡啶-2-基)-1,2,4-噁二唑-5-基)-2,2-二甲基丙酰胺基)烯-1-羧酸叔丁酯 | 917911-03-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-(3-(5-((4-甲氧基苄基)氧基)吡啶-2-基)-1,2,4-噁二唑-5-基)-2,2-二甲基丙酰胺基)烯-1-羧酸叔丁酯
• 英文名称: Methyl 2-(3-(3-(5-((4-methoxybenzyl)oxy)pyridin-2-yl)-1,2,4-oxadiazol-5-yl)-2,2-dimethylpropanamido)cyclohex-1-enecarboxylate
• 英文别名: methyl 2-[[3-[3-[5-[(4-methoxyphenyl)methoxy]pyridin-2-yl]-1,2,4-oxadiazol-5-yl]-2,2-dimethylpropanoyl]amino]cyclohexene-1-carboxylate
• CAS: 917911-03-6
• 化学式: C₂₈H₃₂N₄O₆
• 分子量: 520.585
• InChiKey: BAZVCGTZEKBKBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  38
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  126
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  2-(3-(5-((4-甲氧基苄基)氧基)吡啶-2-基)-1,2,4-噁二唑-5-基)-2,2-二甲基丙酰胺基)烯-1-羧酸叔丁酯 在 三异丙基硅烷 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 Methyl 2-[[3-[3-(5-hydroxypyridin-2-yl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylpropanoyl]amino]cyclohexene-1-carboxylate
  参考文献：
  名称：

  Discovery of a Biaryl Cyclohexene Carboxylic Acid (MK-6892): A Potent and Selective High Affinity Niacin Receptor Full Agonist with Reduced Flushing Profiles in Animals as a Preclinical Candidate

  摘要：

  Biaryl cyclohexene carboxylic acids were discovered as full and potent niacin receptor (GPR109A) agonists. Compound le (MK-6892) displayed excellent receptor activity, good PK across species, remarkably clean off-target profiles, good ancillary pharmacology, and superior therapeutic window over niacin regarding the FFA reduction versus vasodilation in rats and dogs.

  DOI：

  10.1021/jm100022r
• 作为产物：
  描述：

  3-[3-[5-[(4-Methoxyphenyl)methoxy]pyridin-2-yl]-1,2,4-oxadiazol-5-yl]-2,2-dimethylpropanamide 、 methyl 2-(trifluoromethylsulfonyloxy)cyclohex-1-enecarboxylate 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 为溶剂， 以92%的产率得到2-(3-(5-((4-甲氧基苄基)氧基)吡啶-2-基)-1,2,4-噁二唑-5-基)-2,2-二甲基丙酰胺基)烯-1-羧酸叔丁酯
  参考文献：
  名称：

  Niacin receptor agonists, compositions containing such compounds and methods of treatment

  摘要：

  本发明涵盖了Formula I的化合物： 以及其药用可接受的盐和水合物，用于治疗动脉粥样硬化、血脂异常等疾病。药物组合物和使用方法也包括在内。

  公开号：

  US20060293364A1

文献信息

• Niacin receptor agonists, compositions containing such compounds and methods of treatment
  申请人：Raghavan Subharekha

  公开号：US20060293364A1

  公开（公告）日：2006-12-28

  The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.

  本发明涵盖了Formula I的化合物： 以及其药用可接受的盐和水合物，用于治疗动脉粥样硬化、血脂异常等疾病。药物组合物和使用方法也包括在内。
• Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
  申请人：Raghavan Subharekha

  公开号：US20100144778A1

  公开（公告）日：2010-06-10

  The present invention encompasses compounds of Formula (I): as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.

  本发明涵盖式(I)的化合物，以及其药学上可接受的盐和水合物，用于治疗动脉粥样硬化、血脂异常等。还包括制药组合物和使用方法。
• US8168649B2
  申请人：——

  公开号：US8168649B2

  公开（公告）日：2012-05-01
• Discovery of a Biaryl Cyclohexene Carboxylic Acid (MK-6892): A Potent and Selective High Affinity Niacin Receptor Full Agonist with Reduced Flushing Profiles in Animals as a Preclinical Candidate
  作者：Hong C. Shen、Fa-Xiang Ding、Subharekha Raghavan、Qiaolin Deng、Silvi Luell、Michael J. Forrest、Ester Carballo-Jane、Larissa C. Wilsie、Mihajlo L. Krsmanovic、Andrew K. Taggart、Kenneth K. Wu、Tsuei-Ju Wu、Kang Cheng、Ning Ren、Tian-Quan Cai、Qing Chen、Junying Wang、Michael S. Wolff、Xinchun Tong、Tom G. Holt、M. Gerard Waters、Milton L. Hammond、James R. Tata、Steven L. Colletti

  DOI：10.1021/jm100022r

  日期：2010.3.25

  Biaryl cyclohexene carboxylic acids were discovered as full and potent niacin receptor (GPR109A) agonists. Compound le (MK-6892) displayed excellent receptor activity, good PK across species, remarkably clean off-target profiles, good ancillary pharmacology, and superior therapeutic window over niacin regarding the FFA reduction versus vasodilation in rats and dogs.